Venture Capital Access Online | The eMarketplace for the Venture Capital Industry


Bookmark and Share   


Contact Us






Venture Capital Database 2015 Now Available!

Clearside Biomedical, Inc. Completes $16 Million Series B Financing

ALPHARETTA, Ga., September 2, 2014-- Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.

Clearside expects to use proceeds from this financing to fund continued development of Clearside’s proprietary suprachoroidal space (SCS) drug administration and advance its CLS-1001 and CLS-1003 programs into Phase 2 trials by the end of 2014.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Clearside’s product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space with Clearside’s proprietary microinjector. Visit for more information.

Clearside Biomedical, Inc.
Charles Deignan, 678-270-4005

News Index

Venture Capital Database 



Latest VC News
VC News Archive
News Search
RSS News Feed

List Your Firm


Venture Capital Database

VCPro Database
Download Trial
Buy Now

VC Tools

VC Pitch
Private Placement Memorandum

Business Plan Tools

Free Business Plan Template
Business Plan Tools



Copyright © 1998-2015 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer